Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia

European Journal of HaematologyVolume 85, Issue 1 p. 86-87 Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia Ayalew Tefferi, Ayalew Tefferi 1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MNSearch for more papers by this authorRalph Levitt, Ralph Levitt 2MeritCare Roger Maris Cancer Center, Fargo, NDSearch for more papers by this authorTerra L. Lasho, Terra L. Lasho 1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MNSearch for more papers by this authorRyan A. Knudson, Ryan A. Knudson 3Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USASearch for more papers by this authorRhett P. Ketterling, Rhett P. Ketterling 3Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USASearch for more papers by this author Ayalew Tefferi, Ayalew Tefferi 1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MNSearch for more papers by this authorRalph Levitt, Ralph Levitt 2MeritCare Roger Maris Cancer Center, Fargo, NDSearch for more papers by this authorTerra L. Lasho, Terra L. Lasho 1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MNSearch for more papers by this authorRyan A. Knudson, Ryan A. Knudson 3Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USASearch for more papers by this authorRhett P. Ketterling, Rhett P. Ketterling 3Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USASearch for more papers by this author First published: 15 June 2010 https://doi.org/10.1111/j.1600-0609.2010.01458.xCitations: 1 Ayalew Tefferi, MD, Mayo Clinic, Rochester MN 55905, USA. Tel: +1 507 284 3159; Fax: +1 507 266 4972; e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. Int J Hematol 2010; 91: 136–9. 10.1007/s12185-009-0471-6 PubMedWeb of Science®Google Scholar 2 Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, Defina, M, Bosi, A, Francesco, L. Insights into JAK2-V617F mutation in CML. Lancet Oncol 2007; 8: 864–6. 10.1016/S1470-2045(07)70295-4 CASPubMedWeb of Science®Google Scholar 3 Pingali SR, Mathiason MA, Lovrich SD, Go RS. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma 2009; 9: E25–9. 10.3816/CLM.2009.n.080 PubMedWeb of Science®Google Scholar 4 Mirza I, Frantz C, Clarke G, Voth AJ, Turner R. Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med 2007; 131: 1719–24. CASPubMedWeb of Science®Google Scholar 5 Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, Grips KH, Franz-Werner J, Büsche G, Kreipe H. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 2008; 22: 1059–62. 10.1038/sj.leu.2404993 CASPubMedWeb of Science®Google Scholar 6 Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, French M. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008; 32: 1608–10. 10.1016/j.leukres.2008.03.004 CASPubMedWeb of Science®Google Scholar 7 Kramer A, Reiter A, Kruth J, Erben P, Hochhaus A, Muller M, Cross NC, Jones AV, Ho AD, Hensel M. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 2007; 8: 658–60. 10.1016/S1470-2045(07)70206-1 CASPubMedWeb of Science®Google Scholar 8 Campiotti L, Appio L, Solbiati F, Ageno W, Venco A. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res 2009; 33: e212–3. 10.1016/j.leukres.2009.06.011 CASPubMedGoogle Scholar 9 Gattenlohner S, Volker HU, Etschmann B, Einsele H, Muller-Hermelink HK. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T). Am J Hematol 2009; 84: 306–7. 10.1002/ajh.21296 PubMedWeb of Science®Google Scholar 10 Conchon MR, Costa JL, Novaes MM, Dorlhiac-Llacer PE, De Alencar Fischer Chamone D, Bendit I. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol 2008; 88: 243–5. 10.1007/s12185-008-0131-2 PubMedWeb of Science®Google Scholar 11 Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, Grardel N, Laï JL, Rose C, Preudhomme C. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008; 22: 1454–5. 10.1038/sj.leu.2405088 CASPubMedWeb of Science®Google Scholar 12 Kim YK, Shin MG, Kim HR, Yang DH, Cho SH, Lee JJ, Chung IJ, Ryang DW, Kim HJ. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res 2008; 32: 993–5. 10.1016/j.leukres.2007.10.018 CASPubMedWeb of Science®Google Scholar 13 Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007; 21: 1103–4. 10.1038/sj.leu.2404591 CASPubMedWeb of Science®Google Scholar 14 Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22. 10.1038/sj.leu.2404955 CASPubMedWeb of Science®Google Scholar 15 Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872–85. 10.1056/NEJMra0902908 CASPubMedWeb of Science®Google Scholar 16 Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010; 24: 105–9. 10.1038/leu.2009.225 CASPubMedWeb of Science®Google Scholar 17 Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, Tefferi A. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2010; 24: 110–4. 10.1038/leu.2009.226 CASPubMedWeb of Science®Google Scholar 18 Lambert JR, Everington T, Linch DC, Gale RE. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 2009; 114: 3018–23. 10.1182/blood-2009-03-209916 CASPubMedWeb of Science®Google Scholar 19 Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41: 450–4. 10.1038/ng.341 CASPubMedWeb of Science®Google Scholar 20 Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115: 2003–7. 10.1182/blood-2009-09-245381 CASPubMedWeb of Science®Google Scholar 21 Schaub FX, Jager R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 2009; 113: 2022–7. 10.1182/blood-2008-07-167056 CASPubMedWeb of Science®Google Scholar 22 Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia 2008; 22: 3–13. 10.1038/sj.leu.2404946 CASPubMedWeb of Science®Google Scholar Citing Literature Volume85, Issue1July 2010Pages 86-87 ReferencesRelatedInformation